# Interest of a Targeted Therapy for the Treatment of a Severe Form of Hypersensitivity to Drug (DRESS Syndrome)

> **NCT06734884** · PHASE2 · NOT_YET_RECRUITING · sponsor: **University Hospital, Lille** · enrollment: 96 (estimated)

## Conditions studied

- DRESS Syndrome

## Interventions

- **DRUG:** Benralizumab 30 MG/ML [Fasenra]
- **DRUG:** Placebo Comparator: Placebo-Control Arm 0.9% Sodium Chloride

## Key facts

- **NCT ID:** NCT06734884
- **Lead sponsor:** University Hospital, Lille
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2027-01-06
- **Primary completion:** 2029-01-05
- **Final completion:** 2029-09-01
- **Target enrollment:** 96 (ESTIMATED)
- **Last updated:** 2026-05-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06734884

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06734884, "Interest of a Targeted Therapy for the Treatment of a Severe Form of Hypersensitivity to Drug (DRESS Syndrome)". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT06734884. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*